Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.30 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16034913 | 0.90 | HSD11B1 (0.38) | HSD11B1DHFRNR1H4 | |
| SCHEMBL16035598 | 0.88 | HSD11B1 (0.39) | HSD11B1DHFRNR1H4 | |
| SCHEMBL16036893 | 0.87 | HSD11B1 (0.41) | HSD11B1DHFRNR1H4KDM4CSLC6A4 | |
| SCHEMBL16035205 | 0.85 | NR1H4 (0.30) | HSD11B1NR1H4 | |
| SCHEMBL16034892 | 0.85 | HSD11B1 (0.42) | HSD11B1DHFRNR1H4KDM4CSLC6A4 | |
| SCHEMBL16035250 | 0.82 | HSD11B1 (0.38) | HSD11B1DHFRNR1H4 | |
| SCHEMBL16035252 | 0.82 | HSD11B1 (0.42) | HSD11B1DHFRNR1H4SLC6A4SLC6A2 | |
| SCHEMBL16037316 | 0.82 | HSD11B1 (0.40) | HSD11B1DHFRNR1H4SLC6A4SLC6A2 | |
| Bicarbonate SCHEMBL18783217 | 0.81 | HSD11B1 (0.39) | HSD11B1DHFRNR1H4MEN1KMT2A | |
| SCHEMBL16035128 | 0.80 | HSD11B1 (0.40) | HSD11B1DHFRNR1H4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970327-B1 | OXABICYCLO [2.2.2]ACID GPR120 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |
| US-8962660-B2 | Oxabicyclo [2.2.2] acid GPR120 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140275173-A1 | OXABICYCLO [2.2.2] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275173-A1 | OXABICYCLO [2.2.2] ACID GPR120 MODULATORS | GPR180, GPR52, GPR55 | HSD11B1 584/4885DHFR 3433/4885NR1H4 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.